RICHMOND HILL, Ontario, Dec. 06, 2019 (GLOBE NEWSWIRE) — Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the voting results of the Company’s annual and special meeting of shareholders held on December 6, 2019 (the “Meeting”). In accordance with section 11.3 of National Instrument 51-102 Continuous Disclosure Obligations, the following is a summary of the results of matters voted on at the Meeting.
There were 20 shareholders represented in person or by proxy at the Meeting holding 83,464,785 common shares, representing approximately 66.80% of Helix’s total issued and outstanding shares.1.           Election of Directors
Bay Street News